{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03889912",
            "orgStudyIdInfo": {
                "id": "R2810-ONC-1787"
            },
            "secondaryIdInfos": [
                {
                    "id": "2024-511440-76-00",
                    "type": "REGISTRY",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma",
            "officialTitle": "A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients With Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma (BCC)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "intralesional-cemiplimab-for-adult-patients-with-cutaneous-squamous-cell-carcinoma-or-basal-cell-carcinoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-04-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-08-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-10-22",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-03-06",
            "studyFirstSubmitQcDate": "2019-03-22",
            "studyFirstPostDateStruct": {
                "date": "2019-03-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC).\n\nThe aim of the study is to evaluate the safety and tolerability (how your body reacts to the drug) of cemiplimab (also known as REGN2810).\n\nThe first part of the study tested several different doses of cemiplimab given weekly for 12 weeks.\n\nThe study is also looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug\n* To see effect of cemiplimab on the tumor\n* How much study drug is in the blood at different times"
        },
        "conditionsModule": {
            "conditions": [
                "Cutaneous Squamous Cell Carcinoma",
                "Basal Cell Carcinoma"
            ],
            "keywords": [
                "CSCC",
                "BCC"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Cohorts A, B, D and H will enroll sequentially (not randomized). Cohort C and I for BCC will enroll in parallel with, and independently of, Cohorts A, B, D and H for CSCC patients",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 113,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cemiplimab",
                    "type": "EXPERIMENTAL",
                    "description": "Three dose cohorts are planned and will follow a 3 + 3 dose-escalation design with cohort expansion. After completion of the above, three additional cohorts (A, B and C) of patients will be evaluated. Cohorts D, H and I may open after completion of Cohort B.\n\nNote: Cohort E through G will not be opened for participation.",
                    "interventionNames": [
                        "Drug: Cemiplimab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cemiplimab",
                    "description": "Each patient will receive intralesional injections of cemiplimab every week (QW), or at less frequent dosing into the lesion at the assigned dose level for 3-12 weeks prior to scheduled surgery",
                    "armGroupLabels": [
                        "Cemiplimab"
                    ],
                    "otherNames": [
                        "REGN2810",
                        "Libtayo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence, nature, and severity of dose limiting toxicities (DLTs) (if any) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) v5",
                    "description": "Dose levels 1-3",
                    "timeFrame": "From the first dose through day 28"
                },
                {
                    "measure": "Incidence, nature, and severity of treatment-emergent adverse events (TEAEs) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) v5",
                    "description": "Dose levels 1-3",
                    "timeFrame": "From the first dose to 90 days after the last dose"
                },
                {
                    "measure": "Incidence and severity of TEAEs graded according to the NCI CTCAE v5",
                    "timeFrame": "From the first dose up to 90 days after the last dose"
                },
                {
                    "measure": "The incidence and severity of injection site reactions (ISRs)",
                    "timeFrame": "From the first dose to 90 days after the last dose"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective response rate (ORR) of index lesion",
                    "description": "Determined by the investigator using the modified World Health Organization (WHO) criteria",
                    "timeFrame": "At baseline and at Week 13"
                },
                {
                    "measure": "Pathologic complete response rate (or end of treatment biopsies, for patients who decline surgery) in index lesion",
                    "timeFrame": "At time of surgery"
                },
                {
                    "measure": "Major pathologic response rate (or end of treatment biopsies, for patients who decline surgery) in index lesion",
                    "timeFrame": "At time of surgery"
                },
                {
                    "measure": "Cemiplimab concentration in serum over time",
                    "timeFrame": "From the first dose up to 90 days after the last dose"
                },
                {
                    "measure": "Incidence of anti-drug antibody (ADA) titers for cemiplimab",
                    "timeFrame": "Up to 90 days after last dose"
                },
                {
                    "measure": "Selection of the recommended dose of cemiplimab for further study based on clinical and pharmacokinetic (PK) observations",
                    "description": "The determination of the phase 2 recommended dose will be based primarily on clinical safety observations, according to the dose escalation scheme.",
                    "timeFrame": "Up to 90 days after last dose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria\n\n1. Dose Escalation: History of recurrent resectable CSCC or BCC (Cohort C and I only) that satisfies conditions as defined in the protocol\n2. Patients must have measurable disease in the index lesion, defined as 1-2 cm in the longest diameter\n3. Eastern Cooperative Oncology Group (ECOG) performance status \u22641\n\nKey Exclusion Criteria\n\n1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-mediated adverse events (imAEs)\n2. Prior treatment with an agent that blocks the programmed cell death 1 (PD-1)/ programmed cell death 1 ligand (PD-L1) pathway.\n3. Prior treatment with other systemic immune modulating agent as defined in the protocol\n4. M1 or N1, N2 (a, b, or c), or N3 CSCC or BCC. Patients with history of metastatic CSCC (distant or nodal), or metastatic BCC (distant or nodal) are excluded unless the disease-free interval is at least 3 years\n5. Concurrent malignancies, other than those with negligible risk of metastasis or death. Patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL), are excluded.\n6. Patients with a history of solid organ transplant\n7. Has received a Coronavirus induced disease of 2019 (COVID-19) vaccination (initial series and booster) within 1 week of planned start of study medication\n\nNote: Other protocol defined Inclusion/Exclusion criteria apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trial Administrator",
                    "role": "CONTACT",
                    "phone": "844-734-6643",
                    "email": "clinicaltrials@regeneron.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trial Management",
                    "affiliation": "Regeneron Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Medical Dermatology Specialists",
                    "status": "RECRUITING",
                    "city": "Phoenix",
                    "state": "Arizona",
                    "zip": "85006",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.44838,
                        "lon": -112.07404
                    }
                },
                {
                    "facility": "Regeneron Research Facility",
                    "status": "WITHDRAWN",
                    "city": "Redwood City",
                    "state": "California",
                    "zip": "94063",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.48522,
                        "lon": -122.23635
                    }
                },
                {
                    "facility": "Therapeutics Clinical Research",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92123",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Dermatology Associates of the Palm Beaches",
                    "status": "RECRUITING",
                    "city": "Delray Beach",
                    "state": "Florida",
                    "zip": "33445",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.46146,
                        "lon": -80.07282
                    }
                },
                {
                    "facility": "Regeneron Research Facility",
                    "status": "COMPLETED",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Regeneron Research Facility",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30342",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Regeneron Research Facility",
                    "status": "COMPLETED",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "Northeast Dermatology Associates",
                    "status": "COMPLETED",
                    "city": "Beverly",
                    "state": "Massachusetts",
                    "zip": "01915",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.55843,
                        "lon": -70.88005
                    }
                },
                {
                    "facility": "NYU Langone",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10017",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Rochester Dermatologic Surgery",
                    "status": "RECRUITING",
                    "city": "Victor",
                    "state": "New York",
                    "zip": "14564",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.98256,
                        "lon": -77.40888
                    }
                },
                {
                    "facility": "Duke Cancer Center",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "INOVA Schar Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.",
            "accessCriteria": "Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency \\[EMA\\], Pharmaceuticals and Medical Devices Agency \\[PMDA\\], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",
            "url": "https://vivli.org/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000002294",
                    "term": "Carcinoma, Squamous Cell"
                },
                {
                    "id": "D000002280",
                    "term": "Carcinoma, Basal Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000018307",
                    "term": "Neoplasms, Squamous Cell"
                },
                {
                    "id": "D000018295",
                    "term": "Neoplasms, Basal Cell"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "asFound": "Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5537",
                    "name": "Carcinoma, Basal Cell",
                    "asFound": "Basal Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M20451",
                    "name": "Neoplasms, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M20439",
                    "name": "Neoplasms, Basal Cell",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000627974",
                    "term": "Cemiplimab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M302522",
                    "name": "Cemiplimab",
                    "asFound": "RAD",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}